Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Non-Deal Roadshow (April 2015)
28 slides from Neurizon Therapeutics's roadshow presentation, April 2015
Slide 1: Broker Presentation April 2015
Broker For personal use only Presentation April 2015 ASX: PAA ACN 094 006 023
Slide 2: Disclaimer
DISCLAIMER For personal use only • This presentation does not constitute investment advice. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or recommendation in relation to the purchase or sale of shares. • Shareholders should not rely on
Slide 3: PharmAust Limited
PHARMAUST LIMITED For personal use only …Fast tracking leading edge technology in cancer therapy…
Slide 4: PharmAust Cancer Programs
PharmAust Cancer Programs For personal use only
Slide 5: Corporate Structure
PHARMAUST LIMITED CORPORATE STRUCTURE For personal use only PHARMAUST LIMITED ASX:PAA 100% 100% Sydney-‐Based Perth-‐Based
Slide 6: Challenging Limitations in Cancer Therapy
PharmAust - > Challenging Limitations in Cancer Therapy For personal use only • Drug Toxicity • Drug Resistance • Cancer Recurrence • Poor Tumour Targeting • Poor Diagnosis ‐> Patients Progressed at Treatment • Optimising Treatment • Survival vs Quality of Life
Slide 7: PharmAust Strategy
PHARMAUST STRATEGY For personal use only • Targeting oncology applications of well established drugs and piggy- Oncology Focus backing” on substantive programmes of major pharmaceutical companies • Engaging a leading clinical oncology units (St George Hospital, Sydney) Leading New and The Royal Adel
Slide 8: Targeted Therapies for Cancer
Targeted Therapies for Cancer For personal use only Recent Examples of New Targeted Therapies DRUG TARGET PEAK PATIENT COMPANY ANNUAL COST SALES HERCEPTIN + BREAST CANCER $6.5Bln $60,000/ GENENTECH/ PACLITAXEL (HER2-‐NEU) ANNUM ROCHE GLEEVEC MULTIPLE CANCERS $4.7Bln $92,000/ NOVARTIS TYROSINE KINAS
Slide 9: Foundations, Relationships and Commercial Cornerstones
Pharmaust Limited Foundations, Relationships and Commercial For personal use only Cornerstones Strategic IP -‐ Granted and Alliances Pending Patents NOVARTIS UNIVERSITY OF ANIMAL HEALTH CAMBRIDGE NEW SOUTH WALES Listed Japanese INNOVATIONS Group Royal Adelaide Hospital THE ST. GEORGE HOSPITAL S CMA
Slide 10: St George Hospital Department of Surgery/Oncology
For personal use only St George Hospital Department of Surgery/Oncology
Slide 11: Monepantel (MPL or PPL-1)
MONEPANTEL (MPL or PPL -1) For personal use only 1. MPL is a new class of anticancer drug 2. MPL can act alone or in combination with standard of care chemotherapy for treatment of cancer 3. Pharmaust has the IP for MPL assigned from the University of NSW
Slide 12: Monepantel's Unique Properties
MONEPANTEL’S UNIQUE PROPERTIES For personal use only v Unlike most cancer drugs, MPL has virtually little or no toxicity based on the toxicology undertaken by Novartis Animal Health v MPL has shown a high degree of selectivity in killing cancer cells over normal cells in culture v Studies in animal
Slide 13: Effect of MPL on Tumour-Bearing Mice
EFFECT OF MPL ON TUMOUR-BEARING MICE For personal use only Dose-finding study of IP administered Drug in nude mice bearing Subcutaneous ovarian tumours (OVCAR-3), SC / IP Control Group VEHICLE Low dose Group High dose group MPL (25 mg/kg) MPL (50 mg/kg) DRUG DRUG
Slide 14: Monepantel Kills Drug Resistant Cancer Cells
Monepantel Kills Drug Resistant Cancer Cells For personal use only • Temozolamide resistant cancer cells are effectively killed by MPL • MPL has little toxicity on “Normal” Human Embryonic Kidney Cells • MPL offers Treatment Optins either singularly or with “Standard of Care”
Slide 15: Effect of MPL on Cancer Cells
EFFECT OF MPL ON CANCER CELLS For personal use only TEMOZOLAMIDE RESISTANT GLIOMA U251 TEMOZOLAMIDE RESISTANT GLIOMA U251 Cell Proliferation (% of Control) 100 75 50 25 0 0 5 10 25 50 [MPL] (µM) HEK [Human Embyonic Kidney cells] 100 Viability (%) 75 NORMAL CELLS 50 25 0 0 10 25 50 Monepantel [µM]
Slide 16: Synergy Between Aminoacetonitriles and Cytotoxic Drugs
SYNERGY BETWEEN AMINOACETONITRILES AND For personal use only CYTOTOXIC DRUGS • Selective Synergy between MPL and cytotoxic drugs on “cancer” cells • Little synergy between MPL and cytotoxic drugs on “normal” cells • Opportunity for “New Class” of drug for cancer • Therapy in conjunction with standar
Slide 17: Synergy with Taxol
Synergy with Taxol For personal use only C o n tro l M P L 2 5 m g /k g M P L 5 0 m g /k g T a x o l 2 .5 m g /k g T a x o l 2 .5 m g /k g + M P L 2 5 m g /k g T a x o l 2 .5 m g /k g + M P L 5 0 m g /k g T a x o l 5 m g /k g T a x o l 5 m g /k g + M P L 2 5 m g /k g T u m o r v o lu m e (m m ) T a
Slide 18: Lack of PPL-1 Toxicity as Measured by Weight Loss
Lack of PPL -1 Toxicity as Measured by Weight Loss For personal use only OVCAR 3 S.C tumour; i.p. injection B o d y W e ig h t 21 C o n tro l 2 m g /k g G e m 2 m g / k g G e m + 2 5 m g /k g M P L 20 A n im a l w e ig h t ( g ) 5 m g / k g G e m + 2 5 m g /k g M P L 5 m g /k g G e m 19 2 m g /k g G
Slide 19: Human Safety Trial - Monepantel
Human Safety Trial - Monepantel For personal use only ACCELERATED ENTRY INTO MAN DUE TO EXTENSIVE TOXICOLOGY BY GLOBAL MAJOR - Patient #1 ‐> Discontinued after 3 days (drug-unrelated death) - Patient #2 ‐> Completed 28 days - Patient #3 ‐> Discontinued after 13 days (urinary tract infection) - Patie
Slide 20: p70S6K
p70S6K For personal use only D e t e r m i n a t io n o f p - P 7 0 S 6 K i n P B M C o f p a t ie n t s t r e a t e d w it h M P L D a y 1 b e fo r e tr e a tm e n t 100 D ay 3 D ay 7 ( % c o n t r o l) p -P 7 0 S 6 K 50 0 R 01 R 101 R 02 R 102 R 202 R 03 Significance at Day 3 p<0.0005 MPLS, R101 MP
Slide 21: Target Markets
Target Markets For personal use only Monepantel offers a new therapeutic regimen with or without standard Chemotherapy. The current Chemotherapy market is US$42 billion/annum.
Slide 22: Canine Trial
Canine Trial No Adverse Events Noted For personal use only • Four Dogs Received MPL (25mg/kg) compassionately • Three Dogs treated with the lowest dose of MPL (25mg/kg) as part of trial Tasteless Formulation of MPL in Soft‐ Gel Capsules
Slide 23: Albendazole for the Treatment of Ascites
Albendazole for the Treatment of Ascites For personal use only Two Clinical Trials Completed Showing: 1. Maximum tolerated dose 2. Benefits in Localised Therapy in the abdomen 3. Significant Inhibition of VEGF
Slide 24: Albendazole Ascites I
Albendazole Ascites I For personal use only
Slide 25: Ascites in Man
Ascites in Man For personal use only 1.2 Reten7on of Albendazole in the Abdomen 1 Albendazole concenra/on (mg/ml) 0.8 0.6 i.p Oral 0.4 0.2 0 0 0.25 1 2 4 8 12 16 24 30 48 72 120 Time a'er drug administra/on (h) Tumour Growing in the Abdomen and producing large quantities of Ascites fluid which diste
Slide 26: Mucin Dissolution
Mucin Dissolution For personal use only Efficacy of a Novel Mucolytic Agent on Pseudomyxoma Peritonei Mucin with Potential for Treatment through Peritoneal Catheters.
Slide 27: Epichem
EPICHEM For personal use only Epichem is a profitable wholly owned subsidiary of PharmAust which provides services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. Epichem turnover is $2.0M/annum. With two state-of-the-art laboratories in Perth and Melbourne,
Slide 28: Contact Details
Contact Details For personal use only DR ROGER ASTON Executive Chairman PharmAust Limited Email: rogeraston@aol.com Phone: 61 (0) 402 762 204